Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and ...

A daily pill that works like Ozempic can help slimmers lose an average of two stone, trials have found. The study of ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

US stocks were mixed Thursday morning as President Trump's sweeping tariffs hit dozens of US trade partners after his ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Shares of the iPhone maker rose nearly 3%, building on the previous session's rally. Apple announced an extra $100 billion ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The sequel to the 2003 Disney classic is a heartening look at today’s familial relationships, with acute tongue-in-cheek ...

Vizient released its Summer 2025 Spend Management Outlook forecasting a 3.35% increase in pharmaceutical prices in 2026 with healthcare providers seeing increased usage in GLP-1 therapies, specialty ...

Eli Lilly and Company (LLY) is currently at $647.70, down $98.67 or 13.22% --Would be lowest close since Jan. 31, 2024, when it closed at $645.61 --On pace for largest percent decrease since Aug. 9, ...

Eli Lilly said this morning that its experimental obesity pill orforglipron fell short of expectations in a late-stage trial, delivering 11.2% weight loss over 72 weeks — less than the 15% to 21% ...

Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...